Factor H binding protein (FHbp) is a virulence factor used by meningococci to evade the host complement system. FHbp elicits bactericidal antibodies in humans and is part of two recently licensed vaccines. Using human complement Factor H (FH) transgenic mice, we previously showed that binding of FH decreased the protective antibody responses to FHbp vaccination. Therefore, in the present study we devised a library-based method to identify mutant FHbp antigens with very low binding of FH. Using an FHbp sequence variant in one of the two licensed vaccines, we displayed an error-prone PCR mutant FHbp library on the surface of Escherichia coli. We used fluorescence-activated cell sorting to isolate FHbp mutants with very low binding of human FH...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Factor H binding protein (FHbp) is a component of two licensed vaccines for prevention of sepsis and...
ABSTRACT The meningococcal 4CMenB vaccine (Bexsero; Novartis) contains four antigens that can elicit...
Factor H binding protein (FHbp) is a virulence factor used by meningococci to evade the host complem...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
The binding of human complement inhibitors to vaccine antigens in vivo could diminish their immunoge...
<div><p><em>Neisseria meningitis</em> remains a leading cause of sepsis and meningitis, and vaccines...
ABSTRACT Two licensed serogroup Bmeningococcal vaccines contain factor H binding protein (FHbp). The...
<div><p>The binding of human complement inhibitors to vaccine antigens <em>in vivo</em> could dimini...
ABSTRACT Two licensed serogroup B meningococcal vaccines contain factor H binding protein (FHbp). Th...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Factor H binding protein (FHbp) is a component of two licensed vaccines for prevention of sepsis and...
ABSTRACT The meningococcal 4CMenB vaccine (Bexsero; Novartis) contains four antigens that can elicit...
Factor H binding protein (FHbp) is a virulence factor used by meningococci to evade the host complem...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
The binding of human complement inhibitors to vaccine antigens in vivo could diminish their immunoge...
<div><p><em>Neisseria meningitis</em> remains a leading cause of sepsis and meningitis, and vaccines...
ABSTRACT Two licensed serogroup Bmeningococcal vaccines contain factor H binding protein (FHbp). The...
<div><p>The binding of human complement inhibitors to vaccine antigens <em>in vivo</em> could dimini...
ABSTRACT Two licensed serogroup B meningococcal vaccines contain factor H binding protein (FHbp). Th...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to ...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies...
Factor H binding protein (FHbp) is a component of two licensed vaccines for prevention of sepsis and...
ABSTRACT The meningococcal 4CMenB vaccine (Bexsero; Novartis) contains four antigens that can elicit...